Vertex Pharmaceuticals Inc  $314.39

Vertex Pharmaceuticals, Inc. is a global biotechnology company in the business of discovering, developing, manufacturing and introducing small molecule medicines for patients with serious diseases. The company is based in Boston, Massachusetts and currently employs 3,900 full-time employees. The company is focused on developing drugs that treat the underlying causes of cystic fibrosis (CF) and has several ongoing clinical and research programs to advance and expand CF treatments. The company's introduced medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Four of their drugs are used to treat people with CF in North America, Europe and Australia. The company has a pipeline of therapies under investigation in other serious diseases where it uses an understanding of the human biology that causes them, including cyclic cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and dystrophy. muscles. Other company pipeline products include CTX001, VX-147, VX-121, VX-561, VX-548, and VX-880.